Biopharma leaders to discuss optimized clinical operations and outsourcing strategies at iiBIG's forum

NewsGuard 100/100 Score

iiBIG and the newly formed Global Biopharmaceutical Advisory Board have jointly planned an event that will focus on one of the most dynamic trends in the pharmaceutical, biotechnology, and medical device industries -- strategic outsourcing. Biopharma CEOs, VPs of Global Operations, and Department Heads will meet at the 4th Annual Global Clinical Trial Partnerships, March 1-2, 2010, in Princeton, New Jersey to discuss the latest strategies for optimizing global operations.

Key issues to be addressed include:

-- Ensuring competitive advantage through proven outsourcing strategies -- Understanding the latest global regulatory updates in pharma and medical device directives -- Sharing lessons learned to overcome multi-regional operational challenges -- Tackling the latest operational, regulatory and ethical issues in emerging markets: Pan-Asia, India, China, and Latin America -- Obtaining proven tools and techniques for successful patient recruitment

To address these issues, an outstanding speaking faculty of senior-level executives along with key operational leaders who handle global outsourcing and alliance management has been secured for this conference. Hear from representatives of large, medium, and small pharmaceutical as well as biotechnology and medical device companies as they share their insights on strategies for optimizing clinical operations and outsourcing. Some key faculty speakers include:

-- Luis Rios-Nogales, MD, PhD, MBA, Regional Medical Director ISMO Latin America Head, MCCD Clinical Research Region, AstraZeneca Latin America -- Christopher C. Gallen, MD, PhD, President and CEO, Neuromed Pharmaceuticals Inc. -- Ross D. Pettit, Vice President Operations, ARIAD Pharmaceuticals -- Christina DiArcangelo, Associate Director, Clinical Contracts and Outsourcing, Department Head, FibroGen, Inc. -- Raymond Panas, PhD, Director of International Clinical Development, Sucampo Pharmaceuticals -- Fidela Moreno, MD, Vice President Global Development, Clinical Site Management & Monitoring, Allergan For complete information about this event visit: www.iibig.com/P1001

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy